Lysosomal Storage Diseases, Nervous System  >>  Replagal (agalsidase alfa)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Replagal (agalsidase alfa) / Samaritan Pharma, Takeda
NCT00097890: Replagal Enzyme Replacement Therapy for Adults With Fabry Disease

Completed
4
25
US
Replagal (Agalsidase Alfa), Replagal
National Institute of Neurological Disorders and Stroke (NINDS)
Fabry Disease
 
12/05
NCT01650779 / 2015-000697-35: A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

Completed
4
15
US
Agalsidase beta, Fabrazyme®
Genzyme, a Sanofi Company
Fabry Disease
03/13
03/13
NCT01997489: Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.

Completed
4
39
Europe
Enzyme replacement, Replagal, Fabrazyme
Rigshospitalet, Denmark
Fabry Disease
09/13
10/14

Download Options